Nutex Health Inc. (NUTX) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Nutex Health Inc. is a physician-led healthcare services company operating 24 hospital facilities across 11 states and a population health management division. The company operates as an out-of-network provider, utilizing an Independent Dispute Resolution (IDR) process to recover claims. Financial data presented reflects retroactive adjustments for 2024 reverse stock splits (1:15 and 1:10).
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $211.8 million | $67.5 million |
| Gross Profit | $118.3 million | $10.2 million |
| Operating Income | $72.2 million | $1.5 million |
| Net Income (Total) | $44.2 million | $(0.5) million |
| Net Income Attributable to Nutex | $14.6 million | $(0.4) million |
| Diluted EPS | $2.56 | $(0.08) |
| Adjusted EBITDA | $72.8 million | $(0.4) million |
| Cash and Equivalents | $87.7 million | $30.0 million |
| Total Debt (Gross) | $43.2 million | $41.4 million |
| Operating Cash Flow | $51.0 million | $3.1 million |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 214% year-over-year, driven primarily by the Hospital Division ($203.9M vs. $60.0M). This was caused by a 20.5% increase in patient visits and higher revenue per visit due to successful IDR arbitration outcomes.
- Stock-Based Compensation: Corporate costs rose significantly due to a $36.1 million stock-based compensation expense (vs. $0.05M in Q1 2024). Approximately 99% of this expense relates to obligations for under-construction and ramping hospitals.
- Profitability: The company transitioned from a net loss to significant net income. Gross margin expanded dramatically from 15% in Q1 2024 to 56% in Q1 2025.
- Liquidity: Cash and cash equivalents doubled from $43.6 million at year-end 2024 to $87.7 million at March 31, 2025, fueled by strong operating cash flows.
Outlook, Risks, and Unusual Items
- Guidance & Strategy: Management expects to open three new hospital facilities by the end of 2025 and launch one-to-three additional Independent Physician Associations (IPAs) annually. The company continues to rely on the IDR process, achieving an 80%+ success rate in Q1 2025.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of March 31, 2025, due to previously identified material weaknesses in IT general controls, segregation of duties, and spreadsheet management. Remediation efforts are ongoing.
- Debt & Leases: The company has $4.9 million remaining availability on lines of credit. Significant lease obligations exist, with finance lease costs totaling $8.3 million for the quarter.
- Regulatory Risk: Operations are subject to the No Surprises Act (NSA), which limits balance billing. The company's revenue model depends heavily on the outcome of IDR arbitrations with insurers.
Investor Verification Checklist
- Sustainability of IDR Revenue: Verify if the 80% arbitration success rate and resulting revenue uplift are sustainable or if insurer pushback is increasing.
- Stock-Based Compensation Volatility: Assess the impact of the $36M non-cash expense on future earnings and whether the "ramping hospital" obligations will continue to inflate expenses.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting controls to ensure future data reliability.
- Noncontrolling Interest (NCI): Note that a significant portion of net income ($29.6M) is attributable to NCI (VIEs), leaving only $14.6M for common shareholders.
- Debt Covenants: Confirm continued compliance with debt covenants, particularly as the company expands with new facility openings.